NCT00986843View on ClinicalTrials.gov

Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

February 28, 2010

Study Completion Date

September 30, 2012

Conditions
Advanced Solid Malignancies
Interventions
DRUG

HM30181AK tablet + Irinotecan tablets

HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT00986843 - Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102) | Biotech Hunter | Biotech Hunter